British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. | With GSK kicking its R&D engine into high gear in ...

Government R&D encompasses all innovative work the government directly pays for, regardless of who does it.

Large cuts to government-funded research and development can endanger American innovation—and the vital productivity gains it supports.

A new Technology Alliance report warns that Washington’s innovation sector is at risk as public investment lags private R&D spending.

A new report on Michigan's innovation ecosystem found that Michigan leads among states with R&D investment, but falls behind in most other areas.

The guidance recommends that public bodies should set a maximum limit for the proportion of R&D budget that, at any one time, should be allocated to 10-year funding.

Investing.com -- GlaxoSmithKline plc (NYSE: GSK) shares gained 2.2% after the pharmaceutical giant reported first-quarter earnings and revenue that exceeded analyst estimates, driven by strong growth ...